JUN 20, 2018 10:30 AM PDT

Panel Discussion: VA Genomics - The Clinic and Research

Speakers
  • Chief Officer of Specialty Care Services, Veteran Health Administration
    Biography
      Dr. Meyer is the Chief Officer of Specialty Care Services and National Director of Genomic Medicine for the Veterans Health Administration. He is a professor of Dermatology and Internal Medicine at the University of Utah Health Sciences Center. He received his Ph.D. in Molecular Genetics from the University of California at Davis. He studied Medicine at the University of Miami, Florida, and has active board certifications in Internal Medicine, Dermatology and Clinical Genetics. Dr. Meyer has responsibility for the Pain service in the VA and he also has overall oversight of VA policy on opioids. He leads the clinical Genomic Medicine Service which is a centralized clinical telehealth service which delivers genetic service to Veterans in over 80 VA hospitals nationwide.
    • Director of Genomic Medicine and Implementation, Department of Veterans Affairs
      Biography
        Ronald M. Przygodzki, M.D. holds a degree in medicine from the Medical University of Warsaw, Poland. He is board certified in anatomic and clinical pathology (American Board of Pathology), with subspecialization in molecular genetic pathology (American Board of Pathology and American Board of Medical Genetics). He has over 25 years of research and clinical experience with over 15 years of administrative experience. He is Director of Genomic in Implementation, and Associate Director of the Genomic Medicine Program. His previous leadership roles (private and public sectors) include being Director, Biomedical Laboratories R&D at the US Department of Veterans Affairs, as Chief of Pathology at the Children's National Medical Center and as Associate Director of the Molecular Diagnostics Laboratory at the Armed Forces Institute of Pathology, all in Washington DC. He conceptualized, drafted and guided implementation of the Million Veterans Program, one of the largest mega-biobank worldwide. Dr. Przygodzki's research expertise and interests are in anatomic and clinical pathology and molecular genomics, spanning from the theoretical to practical clinically translatable arenas. He has developed unique molecular-based techniques-in particular, ones invented around the use of small archival tissue specimens typically found in pathology. He has authored numerous publications, book chapters, and books. Some of his molecular pathology research efforts led to the reclassification of two pulmonary malignancies by the World Health Organization, and have allowed him to receive national and international recognition. His current aims are targeting pharmacogenomic combinatorial analyses to help guide opioid and major depression therapies.

      Abstract

      With nearly 9 million covered lives serviced through over 150 medical centers, the VA is one of the largest, unified Healthcare System within the United States. Embedded within this system is a large intramural research program spanning biomedical, clinical, rehabilitative and healthcare delivery research program. Just over  10 years ago, the Veterans Healthcare Administration declared a need to invest in genomic medicine both in research and healthcare delivery. Ronald M. Przygodzki, MD, was brought on to build out the genomic medicine program within the Office of Research and Development, ultimately conceptualizing and leading the efforts to develop the Million Veterans Program, the largest genomic research biobank worldwide. He currently is developing the bridge between genomic research and clinic  as Director, Genomic Medicine Implementation. Dr. Laurence J. Meyer, MD, PhD, was brought on as the National Director, Genomic Medicine where he developed a nationwide telehealth genetic counseling program that services the VA Healthcare system nationwide. Currently, he is the Chief Officer, Specialty Care Services where he leads the modernization of VA healthcare. Both Ron and Larry will be presenting strategies, lessons learned and goals withn genomic medicine to provide the best healthcare to our nation's Veterans. 


      Show Resources
      You May Also Like
      SEP 10, 2020 9:00 AM PDT
      C.E. CREDITS
      SEP 10, 2020 9:00 AM PDT
      Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
      DEC 02, 2020 8:00 AM PST
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      OCT 08, 2020 7:00 AM PDT
      C.E. CREDITS
      OCT 08, 2020 7:00 AM PDT
      DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
      NOV 18, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 18, 2020 8:00 AM PST
      DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      OCT 29, 2020 6:00 AM PDT
      C.E. CREDITS
      OCT 29, 2020 6:00 AM PDT
      Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
      Loading Comments...
      Show Resources